Sponsors

Micafungin added to fungal susceptibility card

bioMérieux has created a new fungal susceptibility card for susceptibility testing of Candida species and Cryptococcus neoformans. The VITEK 2 ASTYS07 card includes a sixth antifungal agent, micafungin, providing a valuable enhancement to antifungal susceptibility testing.

Yeast infections have become a major cause of morbidity and mortality in at-risk patient populations. Early diagnosis and prompt treatment are key to achieving successful outcomes in these infections, and bioMérieux’s VITEK 2 instrument offers automated, standardised and rapid yeast susceptibility
testing.

The VITEK 2 AST-YS07 fungal susceptibility card, which replaces VITEK 2 AST-YS06, complements the current antifungals – amphotericin B, caspofungin, fluconazole, flucytosine and voriconazole – with micafungin, an echinocandin active against Candida species, extending the capabilities of the
VITEK 2 and helping to ensure that the correct treatment is initiated swiftly.
www.biomerieux.com

Latest Issues

Pathology Visions 24

Hyatt Regency, Orlando, FL
3-5 November, 2025

UK NEQAS Cellular Pathology Technique - Annual Participant’s Meeting

America Square Conference Centre, London, EC3N 2LB.
4 - 5 November, 2024

Medica

Messe Dusseldorf
11-14 November, 2024

POCT-for-Scot: Bringing the future to you

SEC Arena, Glasgow
14 November, 2024

Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo

Hyatt Regency, Vancouver, Canada
19-23 November, 2024